Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
Merck Sharp & Dohme,Pembrolizumab,"Non small cell lung cancer, locally advanced or metastatic, PD-L1 positive, 2nd line",Pembrolizumab (Keytruda),Community and Hospital,Oncology Agents and Immunosuppressants
